Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Primary Hypertrophic Osteoarthropathy: An Update on Patient Features and Treatment

GABRIELLA GIANCANE, CHRISTINE P. DIGGLE, ELIZABETH G. LEGGER, JANNEKE TEKSTRA, BERENT PRAKKEN, ARJAN B. BRENKMAN, IAN M. CARR, ALEXANDER F. MARKHAM, DAVID T. BONTHRON and NICO WULFFRAAT
The Journal of Rheumatology November 2015, 42 (11) 2211-2214; DOI: https://doi.org/10.3899/jrheum.150364
GABRIELLA GIANCANE
Department of Pediatric Immunology, University Medical Centre Utrecht (UMC), Utrecht, the Netherlands;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gabriella.giancane{at}gmail.com ggiancan{at}umcutrecht.nl
CHRISTINE P. DIGGLE
School of Medicine, St. James’s University Hospital, University of Leeds, Leeds, UK;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELIZABETH G. LEGGER
Department of Pediatric Immunology, UMC;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JANNEKE TEKSTRA
Department of Rheumatology & Clinical Immunology, UMC;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BERENT PRAKKEN
Laboratory for Translational Immunology, UMC;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARJAN B. BRENKMAN
Department of Metabolic and Endocrine Diseases, UMC;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IAN M. CARR
School of Medicine, St. James’s University Hospital, University of Leeds;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDER F. MARKHAM
School of Medicine, St. James’s University Hospital, University of Leeds;
BSc, PhD, MB, BS, DSc, FRCP, FRCPath
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID T. BONTHRON
School of Medicine, St. James’s University Hospital, University of Leeds;
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICO WULFFRAAT
Department of Pediatric Immunology, UMC.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

Hypertrophic osteoarthropathy (HO) is a disorder characterized by changes to the skin and bones, and occurs either in a rare familial primary form [primary hypertrophic osteoarthropathy, (PHO)], also called pachydermoperiostosis (PDP), with a 9:1 male:female prevalence ratio, or more commonly secondary to an underlying pathology1. Key features include digital clubbing, periostosis with bone and joint enlargement, and skin changes, such as pachydermia, abnormal furrowing, seborrhea, and hyperhidrosis. Specific developmental abnormalities have been found in some patients with PHO, such as wide cranial sutures, Wormian bones, and patent ductus arteriosus2. In adults, when all major clinical features are present, PHO is relatively easy to diagnose. However, for the pediatrician, who often has to contend with an incomplete clinical presentation3, diagnosis may be a challenge. The discovery of mutations in 2 prostaglandin pathway genes HPGD and SLCO2A1 has clarified the autosomal recessive inheritance [Mendelian Inheritance in Man (MIM) #259100, MIM #614441] of this genetically heterogeneous condition4,5,6,7.

Here we present 4 previously undescribed patients who exemplify the gene-dependent presentations of PHO and provide diagnostic and treatment advice.

The subjects’ written consent was obtained in conformance to the Declaration of Helsinki.

Key clinical features are listed in Table 1. Secondary causes of HO were excluded8, and DNA sequence analysis (Supplementary Data available online at jrheum.org) confirmed the clinical diagnoses of PHO/PDP.

View this table:
  • View inline
  • View popup
Table 1.

Patients’ clinical features.

Case Report. Patient 1

A 20-year-old male patient had begun limping at the age of 14 months. At 3 years old, chronic arthritis of both knees was investigated by arthroscopy, with nonspecific chronic synovial inflammation at biopsy. Oligoarticular juvenile idiopathic arthritis (JIA) was diagnosed, and the patient was treated with nonsteroidal antiinflammatory drugs (NSAID), with clinical improvement. At age 5, coarse facies was noted. Tests for autoimmune diseases and mucopolysaccharidosis were normal. In the following years, the frequent relapses with arthritis required synovectomy, intraarticular steroid injections, immunosuppressive therapies [sulfasalazine (SSZ) and then methotrexate (MTX)], and tumor necrosis factor-α–blocking agents (etanercept and adalimumab), with modest efficacy. From the age of 12 years, “watch-glass” nails and digital clubbing started to develop (Supplementary Figure 1 available online at jrheum.org), associated with a worsening pachydermia and furrowing of the forehead, leading to the clinical suspicion of PHO. The diagnosis was supported by elevated prostaglandin E2 (PGE2) levels (Supplementary Table 1 available online at jrheum.org) and by sequencing HPGD, which identified 2 reported heterozygous mutations2,4(Table 1; Supplementary Figure 2 available online at jrheum.org). High-dose therapy with NSAID (ibuprofen 30 mg/kg/day) was started and is currently maintained, with clinical improvement but incomplete recovery.

Patient 2

A 21-year-old male patient was first admitted at age 13 because of isolated swelling and pain in the knees. This was diagnosed as oligoarticular JIA and treated with local steroid injections, and afterward with NSAID and SSZ because of persisting arthritis. Arthroscopy with biopsy and synovial fluid analysis confirmed nonspecific chronic synovitis. In the following years, the extension of the disease to the wrists, hips, ankles, and spine led to the use of MTX (15 mg/m2/week) and NSAID (diclofenac 2 mg/kg/day), with low efficacy. At age 18, the patient started to develop severe aplastic anemia, requiring multiple transfusions, and thrombocytopenia, progressively associated with mild leukopenia (Figure 1). Bone marrow examination showed hypocellularity (< 5% to 40%), trilinear hematopoiesis with dyserythropoiesis, and moderate reticular fibrosis. Maintenance therapy of prednisone (PRED) 35 mg/day was started and then gradually tapered. Hyperhidrosis and thickening of the skin with cutis verticis gyrata and seborrhea also became increasingly evident (Supplementary Figure 3 available online at jrheum.org). No digital clubbing was observed. PHO was suspected, and elevated PGE2 (Supplementary Table 1 available online at jrheum.org) and DNA sequencing confirmed this diagnosis. Compound heterozygosity for 2 nonsense mutations in SLCO2A1 was found: c.754C>T (p.R252X), previously described9, and c.794C>G (p.S265X), which was novel (Table 1; Supplementary Figure 3 available online at jrheum.org). The patient continued receiving ibuprofen 400 mg 3 times per day, combined with low-dose steroid therapy (PRED 10 mg/day) for myelofibrosis. The hematological picture improved dramatically, achieving complete normalization. The patient had no further joint relapses, but followup radiographs of the hands, knees, and ankles showed metacarpal and fibular bilateral periostosis (Supplementary Figure 4 available online at jrheum.org). Generalized hyperhidrosis required oxybutynin 2.5 mg 3 times per day, with great efficacy. Considering the stabilization of the rheumatological and hematological picture, and the risk of worsening thrombocytopenia, NSAID were stopped and used again only in the last year for episodes of back pain.

Hemoglobin, platelet, and leukocyte patterns in Patient 2 over time. The level of (A) hemoglobin, (B) platelets, and (C) leukocytes was monitored over 6 years. Normal ranges (areas between the dashed lines): hemoglogin: 8.6–10.7 mmol/l; platelets: 150–450 × 109/l; and leukocytes: 4–10 × 109/l.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Hemoglobin, platelet, and leukocyte patterns in Patient 2 over time. The level of (A) hemoglobin, (B) platelets, and (C) leukocytes was monitored over 6 years. Normal ranges (areas between the dashed lines): hemoglogin: 8.6–10.7 mmol/l; platelets: 150–450 × 109/l; and leukocytes: 4–10 × 109/l.

Patient 3

A 15-year-old girl was first evaluated at the age of 9 for arthralgias in the knees, back, and ankles. She also had hyperhidrosis and a history of delayed suture closure. Over time, more pronounced coarse facial features developed. At 11 years old, she had signs of active arthritis in the knees, hands, hips, and feet, with normal laboratory tests and radiographs. Only magnetic resonance imaging (MRI) showed chronic arthritis in the left wrist. Therapy with NSAID (indomethacin 1 mg/kg/day) was started, with remarkable improvement of joint involvement and pain relief. At 15 years old, the patient relapsed with arthritis of the knees, associated for the first time with digital clubbing, hyperhidrosis, and mild anemia. A brief period of MTX (15 mg/m2/week) was tried with no effect. PHO was diagnosed through the genetic testing of HPGD, identifying the homozygous c.120delA mutation (Table 1). Indomethacin was doubled with significant clinical improvement, both in the joint and skin involvement. The dysmorphic features did not progress.

Patient 4

This male child was evaluated at the age of 2.5 years after preterm birth (33 + 4 weeks, birth weight 1700 g) for swelling and stiffness of the knees, gradually followed by involvement of the ankles, toes, and hands. Throughout the course of his disease, he had required surgery for a patent ductus arteriosus and physical therapy, including helmet remodeling, in the first months of his life for brachy-plagiocephaly. Delayed suture closure and late motor development and speech/language were observed. Physical examination also identified hyperhidrosis of the hands. Blood tests including antinuclear antibody, rheumatoid factor and inflammatory markers, ultrasound scan of the skull, and MRI of the knees were normal. Treatment with NSAID (ibuprofen 20 mg/kg/day) was started with positive results. At 3 years, bony enlargement of the distal phalanges and a thickened skull were revealed by radiographs. At age 4, PHO was diagnosed by the identification of 2 compound heterozygous HPGD mutations: c.175_176delCT and the novel c.298T>C (p.W100R; Table 1; Supplementary Data and Supplementary Figure 5 available online at jrheum.org). The patient was treated with ibuprofen, initially at 20 mg/kg/day and subsequently as necessary, with a stable clinical pattern requiring therapy around 2–3 times a week.

Here we have described 4 patients with PHO/PDP with HPGD or SLCO2A1 deficiency [OMIM#259100, autosomal recessive primary hypertrophic osteoarthropathy (PHOAR) 1 and #614441, PHOAR2, respectively].

Although mutations in either HPGD or SLCO2A1 cause PHO/PDP, there are phenotypic differences associated with each gene exemplified in patients 1 and 2, who had mutations in HPGD and SLCO2A1, respectively. Patient 1 developed initial symptoms much earlier than patient 2. The onset of PHO is usually before the age of 20, but its biphasic incidence is now attributed to the genetic heterogeneity, with onset of symptoms in early childhood for HPGD patients and during puberty/early adulthood for SLCO2A1 patients5,6,9,10,11,12,13.

Patients with SLCO2A1 mutations, such as patient 2, have been described as having more severe symptoms overall6,9,11, the presence of skin folds (as cutis verticis gyrata)5,12, and chronic anemia and/or pancytopenia, secondary to hypocellular myelofibrosis5,14,15. On the other hand, patients 3 and 4 exhibited delayed cranial suture closure that has led to the use of the term “cranio-osteoarthropathy”. This has only been seen in patients with HPGD mutations2,4,12,16.

The histories of our patients suggest approaches for clinical practice. For example, young children with swollen and painful joints and a history of patent ductus arteriosus, delayed closure of the cranial sutures, and fontanelles or Wormian bones should be investigated immediately for PHO because clubbing, periostosis, and skin changes might be absent. When PHO/PDP is suspected, secondary causes have to be excluded. Blood and early morning urine can be considered for prostaglandin measurement, but their detection is not feasible in all laboratories, and implications in differential diagnosis, followup, and treatment still need to be studied and standardized with age-related values13. In contrast, sequence analysis of both genes is simple and cheap, and therefore should be considered as an early investigation when PHO/PDP is suspected because it can provide confirmation of diagnosis. The presence of chronic arthritis often leads to a diagnosis of JIA. Nevertheless, a patient with JIA, nonresponder to DMARD and biological therapies, and with a better response to NSAID, should be considered as having another disease and investigated for further clinical signs. Indeed, HPGD and SLCO2A1 patients usually experience some positive effects on joint pain and swelling while being treated with NSAID5,12,16,17,18, but it is uncertain if either the use of indomethacin compared with ibuprofen could provide better results clinically, as for patient 3, or if the phenotype of this patient is milder as a consequence of being female.

Myelofibrosis is a life-threatening complication; consequently, when germline SLCO2A1 mutations are detected, the patient should be followed up periodically for myelofibrosis. The use of steroids can produce hematological improvement, but no effects on skin or digital clubbing, and longer-term treatment may help in symptom stabilization19. NSAID appear to be the best option for treatment, while other treatments can be evaluated individually, but support for their use is largely anecdotal20,21,22.

ONLINE SUPPLEMENT

Supplementary data for this article are available online at jrheum.org.

Footnotes

  • Supported in part by a grant from Cancer Research UK, MRC MR/L01629X/1, and a Wellcome Trust VIP award.

REFERENCES

  1. 1.↵
    1. Friederich N
    . [Archive for pathological anatomy and physiology and for clinical medicine]. [Article in French] Arch Path Anat 1868;43:83–7.
    OpenUrlCrossRef
  2. 2.↵
    1. Seifert W,
    2. Beninde J,
    3. Hoffmann K,
    4. Lindner TH,
    5. Bassir C,
    6. Aksu F,
    7. et al.
    HPGD mutations cause cranioosteoarthropathy but not autosomal dominant digital clubbing. Eur J Hum Genet 2009;17:1570–6.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Latos-Bielenska A,
    2. Marik I,
    3. Kuklik M,
    4. Materna-Kiryluk A,
    5. Povysil C,
    6. Kozlowski K
    . Pachydermoperiostosis-critical analysis with report of five unusual cases. Eur J Pediatr 2007;166:1237–43.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Uppal S,
    2. Diggle CP,
    3. Carr IM,
    4. Fishwick CW,
    5. Ahmed M,
    6. Ibrahim GH,
    7. et al.
    Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008;40:789–93.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Diggle CP,
    2. Parry DA,
    3. Logan CV,
    4. Laissue P,
    5. Rivera C,
    6. Restrepo CM,
    7. et al.
    Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat 2012;33:1175–81.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Seifert W,
    2. Kühnisch J,
    3. Tüysüz B,
    4. Specker C,
    5. Brouwers A,
    6. Horn D
    . Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat 2012;33:660–4.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Zhang Z,
    2. Xia W,
    3. He J,
    4. Zhang Z,
    5. Ke Y,
    6. Yue H,
    7. et al.
    Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet 2012;90:125–32.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Pineda C,
    2. Martínez-Lavín M
    . Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin North Am 2013;39:383–400.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Cheng R,
    2. Li M,
    3. Guo Y,
    4. Yao Y,
    5. Gao C,
    6. Yao Z
    . Three novel mutations in the SLCO2A1 gene in two Chinese families with primary hypertrophic osteoarthropathy. Eur J Dermatol 2013;23:636–9.
    OpenUrlPubMed
  10. 10.↵
    1. Zhang Z,
    2. He JW,
    3. Fu WZ,
    4. Zhang CQ,
    5. Zhang ZL
    . A novel mutation in the SLCO2A1 gene in a Chinese family with primary hypertrophic osteoarthropathy. Gene 2013;521:191–4.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Madruga Dias JA,
    2. Rosa RS,
    3. Perpétuo I,
    4. Rodrigues AM,
    5. Janeiro A,
    6. Costa MM,
    7. et al.
    Pachydermoperiostosis in an African patient caused by a Chinese/Japanese SLCO2A1 mutation-case report and review of literature. Semin Arthritis Rheum 2014;43:566–9.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Tüysüz B,
    2. Yılmaz S,
    3. Kasapçopur O,
    4. Erener-Ercan T,
    5. Ceyhun E,
    6. Bilguvar K,
    7. et al.
    Primary hypertrophic osteoarthropathy caused by homozygous deletion in HPGD gene in a family: changing clinical and radiological findings with long-term follow-up. Rheumatol Int 2014;34:1539–44.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Zhang Z,
    2. He JW,
    3. Fu WZ,
    4. Zhang CQ,
    5. Zhang ZL
    . Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: A clinical and biochemical characterization. J Clin Endocrinol Metab 2013;98:923–33.
    OpenUrlCrossRef
  14. 14.↵
    1. Castori M,
    2. Sinibaldi L,
    3. Mingarelli R,
    4. Lachman RS,
    5. Rimoin DL,
    6. Dallapiccola B
    . Pachydermoperiostosis: an update. Clin Genet 2005;68:477–86.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Fontenay-Roupie M,
    2. Dupuy E,
    3. Berrou E,
    4. Tobelem G,
    5. Bryckaert M
    . Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis. Blood 1995;85:3229–38.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Bergmann C,
    2. Wobser M,
    3. Morbach H,
    4. Falkenbach A,
    5. Wittenhagen D,
    6. Lassay L,
    7. et al.
    Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15-PGHD/HPGD loss-of-function mutations. Exp Dermatol 2011;20:531–3.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Erken E,
    2. Köroğlu Ç,
    3. Yıldız F,
    4. Özer HT,
    5. Gülek B,
    6. Tolun A
    . A novel recessive 15-hydroxyprostaglandin dehydrogenase mutation in a family with primary hypertrophic osteoarthropathy. Mod Rheumatol 2015;25:315–21.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Diggle CP,
    2. Carr IM,
    3. Zitt E,
    4. Wusik K,
    5. Hopkin RJ,
    6. Prada CE,
    7. et al.
    Common and recurrent HPGD mutations in Caucasian individuals with primary hypertrophic osteoarthropathy. Rheumatology 2010;49:1056–62.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Ninomiya S,
    2. Hara T,
    3. Tsurumi H,
    4. Kanemura N,
    5. Kasahara S,
    6. Ogawa Y,
    7. et al.
    Myelofibrosis successfully treated with prednisolone in a patient with pachydermoperiostosis. Intern Med 2011;50:2207–11.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Jojima H,
    2. Kinoshita K,
    3. Naito M
    . A case of pachydermoperiostosis treated by oral administration of a bisphosphonate and arthroscopic synovectomy. Mod Rheumatol 2007;17:330–2.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Warwas S,
    2. Specker C,
    3. Jäger M,
    4. Landgraeber S
    . Arthroscopic synovectomy and radiosynoviorthesis: a treatment option for recurrent arthritis symptoms in patients with pachydermoperiostosis. Reumatismo 2013;65:82–5.
    OpenUrlPubMed
  22. 22.↵
    1. da Costa FV,
    2. de Magalhães Souza Fialho SC,
    3. Zimmermann AF,
    4. Neves FS,
    5. Werner de Castro GR,
    6. Pereira IA
    . Infliximab treatment in pachydermoperiostosis: a rare disease without an effective therapeutic option. J Clin Rheumatol 2010;16:183–4.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 42, Issue 11
1 Nov 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Primary Hypertrophic Osteoarthropathy: An Update on Patient Features and Treatment
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Primary Hypertrophic Osteoarthropathy: An Update on Patient Features and Treatment
GABRIELLA GIANCANE, CHRISTINE P. DIGGLE, ELIZABETH G. LEGGER, JANNEKE TEKSTRA, BERENT PRAKKEN, ARJAN B. BRENKMAN, IAN M. CARR, ALEXANDER F. MARKHAM, DAVID T. BONTHRON, NICO WULFFRAAT
The Journal of Rheumatology Nov 2015, 42 (11) 2211-2214; DOI: 10.3899/jrheum.150364

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Primary Hypertrophic Osteoarthropathy: An Update on Patient Features and Treatment
GABRIELLA GIANCANE, CHRISTINE P. DIGGLE, ELIZABETH G. LEGGER, JANNEKE TEKSTRA, BERENT PRAKKEN, ARJAN B. BRENKMAN, IAN M. CARR, ALEXANDER F. MARKHAM, DAVID T. BONTHRON, NICO WULFFRAAT
The Journal of Rheumatology Nov 2015, 42 (11) 2211-2214; DOI: 10.3899/jrheum.150364
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Case Report. Patient 1
    • Patient 2
    • Patient 3
    • Patient 4
    • ONLINE SUPPLEMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Joint Localization Matters
  • Hepatic Involvement in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Clinical and Therapeutic Insights From 2 Cases
  • Lung Ultrasound in Rheumatoid Arthritis–Associated Interstitial Lung Disease: Beyond a Promising Tool
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire